FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective-Reference-Cited by-同舟云学术

FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective

Published:2023-03-04 Issue:6 Volume:50 Page:1553-1555
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Verger Antoine,Yakushev Igor,Albert Nathalie L.,van Berckel Bart,Brendel Matthias,Cecchin Diego,Fernandez Pablo Aguiar,Fraioli Francesco,Guedj Eric,Morbelli Silvia,Tolboom Nelleke,Traub-Weidinger Tatjana,Van Weehaeghe Donatienne,Barthel Henryk

Funder

Technische Universität München

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-023-06177-5.pdf

Reference20 articles.

1. Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021;13:80.

2. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:9–21.

3. Planche V, Villain N. US Food and Drug Administration approval of aducanumab—is amyloid load a valid surrogate end point for Alzheimer disease clinical trials? JAMA Neurol. 2021;78:1307.

4. Dhadda S, Kanekiyo M, Li D, Swanson CJ, Irizarry M, Berry S, et al. Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease. Alzheimers Res Ther. 2022;14:182.

5. Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al. Lecanemab, aducanumab, and gantenerumab — binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer’s disease. Neurotherapeutics 2022. https://doi.org/10.1007/s13311-022-01308-6

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: an update of the literature;Expert Review of Neurotherapeutics;2024-09-04

2. α-Lipoic acid: a potential regulator of copper metabolism in Alzheimer’s disease;Frontiers in Molecular Biosciences;2024-09-03

3. Evaluation of a novel PET tracer [18F]-Florbetazine for Alzheimer's disease diagnosis and β-amyloid deposition quantification;NeuroImage;2024-09

4. Investigation of the Impact of the H310A FcRn Region Mutation on 89Zr-Immuno-PET Brain Imaging with a BBB-Shuttle Anti‑Amyloid Beta Antibody;Molecular Imaging and Biology;2024-08-02

5. A Comparative Analysis of Two Automated Quantification Methods for Regional Cerebral Amyloid Retention: PET-Only and PET-and-MRI-Based Methods;International Journal of Molecular Sciences;2024-07-12